Lilly Executes Six Major Acquisitions in H2 2023, Expanding Footprint in Obesity and Oncology

　　【Pharmaceutical Network Industry DynamicsSince the second half of 2023, Eli Lilly and Company has frequently made significant acquisition moves, with a total of six acquisitions already carried out. Except for September, there have been acquisition activities almost every month.
 

In October, Eli Lilly announced that it would acquire cancer biotechnology company POINT Biopharma (NASDAQ: PNT) for approximately $1.4 billion in cash. POINT Biopharma's key projects include PNT2002 and PNT2003, which are currently in the late stages of development. PNT2002 is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, while PNT2003 is a radioligand therapy targeting somatostatin receptors (SSTR).
 

In October, media reports stated that Eli Lilly and Company had agreed to acquire Mablink Bioscience, a French biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment.
 

In August, Eli Lilly and Company successively announced the completion of acquisitions of DICE Therapeutics and Sigilon Therapeutics for $2.4 billion and $14.92 per share, respectively. DICE Therapeutics is a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates, including an oral IL-17 inhibitor currently in clinical development for the treatment of chronic diseases in immunology. Sigilon Therapeutics is developing experimental cell therapies that could provide long-term solutions for patients with diabetes.
 

On July 14, Eli Lilly announced the acquisition of Versanis, a non-public company, for $1.925 billion. Through this deal, Eli Lilly will add a new asset to its weight loss pipeline from Versanis Bio. Versanis is a private clinical-stage biopharmaceutical company focused on developing new drugs for cardiometabolic diseases. Its leading asset, bimagrumab, is currently undergoing the BELIEVE Phase 2b study as a new therapy to help adults achieve and maintain fat reduction and a healthy body composition, with other indications also being explored.
 

In addition, in June, Eli Lilly acquired Emergence Therapeutics, bringing the latter's core pipeline, Nectin-4 ADC, into its portfolio.
 

Currently, Eli Lilly's main businesses focus on disease areas such as diabetes, immunology, and neurology. From the direction of Eli Lilly's acquisitions this year, the focus has been on weight loss, oncology, and nuclear medicine fields.
 

The analysis suggests that the purpose of the acquisition may be to achieve synergy with the parent company and enhance overall efficiency. According to the principles of pharmaceutical companies' market value management, through high-quality acquisitions, Eli Lilly can secure key track assets and obtain product pipelines in a highly efficient and lower-risk manner, thereby expanding its therapeutic areas or technical platform coverage. Additionally, it can fully leverage its existing development capabilities and commercialization platforms to achieve complementary advantages.
 

Among them, weight-loss drugs have continued to be a hot topic in the market this year. Analysts believe that by 2030, the annual sales of the global anti-obesity drug market may grow to around $100 billion, up from approximately $6 billion earlier this year. This projection is based on around 15 million American adults receiving anti-obesity drug treatments for chronic weight management by 2030, out of about 105 million obese or overweight adults in the United States.
 

Eli Lilly's Q2 and H1 2023 financial results show that the total revenue for the first half of the year was $15.272 billion, a year-on-year increase of 7%. Specifically, Q2 revenue reached $8.312 billion, marking a 28% year-on-year growth. Boosted by this, its stock price surged by 14.87%, even hitting $538 per share during trading, with a market value surpassing $500 billion.
 

Driven by the "weight-loss wonder drug" Mounjaro, Eli Lilly's new products contributed $1 billion in revenue in the second quarter. Looking ahead, Eli Lilly has raised its 2023 earnings per share guidance by $1.02 to $9.20-$9.40; non-GAAP earnings per share guidance was increased by $1.05 to $9.70-$9.90, surpassing market expectations of $8.75.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.